ReviewFrontiers in immunology2026
Extracellular vesicle-mediated immune remodeling in cutaneous wound repair.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Extracellular vesicles (EVs) are emerging cell-free therapeutic platforms for cutaneous wound repair that regulate diverse cellular processes, including intercellular communication, inflammation, angiogenesis, extracellular matrix remodeling, and tissue repair. Recent advances in parental cell preconditioning, EV engineering, smart EV design, and biomaterial-assisted delivery have further enhanced the therapeutic potential of EV-based approaches. These advances have stimulated growing interest in applying EVs to skin wound repair, where EVs act on resident skin cells and immune cells to promote regenerative healing. In particular, macrophage reprogramming is well characterized, whereas EV-mediated regulation of other immune-cell populations remains less clearly defined. Standardized EV production, reliable potency assays, and dynamic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.